Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis

Published:2020-01-01 Issue:1 Volume:9 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Nugteren Sandrine¹,Goos Jeroen A.C.M.²,Delis-van Diemen Pien M.³,Simons-Oosterhuis Ytje¹,Lindenbergh-Kortleve Dicky J.¹,van Haaften Daniëlle H.¹,Sanders Joyce³^ORCID,Meijer Gerrit A.³^ORCID,Fijneman Remond J.A.³,Samsom Janneke N.¹

Affiliation:

1. Laboratory of Pediatrics, Division Gastroenterology and Nutrition, Erasmus University Medical Center, Rotterdam, The Netherlands

2. Departments of Clinical Neuroscience, Radiopharmacy, and Oncology & Pathology, Karolinska Institute, Stockholm, Sweden

3. Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Funder

the Dutch Digestive Foundation

Dutch Digestive Foundation

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2020.1832761

Reference45 articles.

1. Modulation of secretory leukoprotease inhibitor gene expression in human bronchial epithelial cells by phorbol ester.

2. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes.

3. Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding

4. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase.

5. Antibacterial activity of antileukoprotease

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer—Results of the prospective multicenter PERMAD trial;PLOS ONE;2024-06-14

2. The chemical composition of Diwu YangGan capsule and its potential inhibitory roles on hepatocellular carcinoma by microarray-based transcriptomics;Journal of Traditional and Complementary Medicine;2023-12

3. Secretory leukocyte protease inhibitor (SLPI) in cancer pathophysiology: Mechanisms of action and clinical implications;Pathology - Research and Practice;2023-08

4. WFDC3 inhibits tumor metastasis by promoting the ERβ-mediated transcriptional repression of TGFBR1 in colorectal cancer;Cell Death & Disease;2023-07-13

5. Dietary iron modulates gut microbiota and induces SLPI secretion to promote colorectal tumorigenesis;Gut Microbes;2023-06-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3